Cantharidin suppresses cell growth and migration, and activates autophagy in human non-small cell lung cancer cells

Liu,Yan‑Peng; Li,Ling; Xu,Liang; Dai,E‑Nuo; Chen,Wei‑Da

doi:10.3892/ol.2018.8141

Cantharidin suppresses cell growth and migration, and activates autophagy in human non-small cell lung cancer cells

Authors:
- Yan‑Peng Liu
- Ling Li
- Liang Xu
- E‑Nuo Dai
- Wei‑Da Chen
View Affiliations

Affiliations: Department of Internal Medicine, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China, Department of Surgery, Affiliated Hospital of Shandong Academy of Medical Sciences, Jinan, Shandong 250031, P.R. China, Department of Geriatric Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, P.R. China
Published online on: March 1, 2018 https://doi.org/10.3892/ol.2018.8141
Pages: 6527-6532

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cantharidin (CTD), a component of Mylabris (blister beetle), is a traditional Chinese medicine that exerts an anticancer effect in multiple types of cancer cells. The aim of the present study was to investigate whether CTD exhibited anti‑metastatic and inhibitory cell proliferation effects against human non‑small cell lung cancer (NSCLC) A549 cells, and the possible underlying mechanism by which this occurs. The results of the present study demonstrated that CTD arrested proliferation, suppressed invasion and migration and induced apoptosis in A549 cells in vitro. Alterations of apoptosis‑associated protein levels, including B‑cell lymphoma‑2 (Bcl‑2), Bcl‑associated X (Bax) and active caspase‑3, were detected. Furthermore, the present study demonstrated that CTD activated autophagy through downregulation of p62 expression and upregulation of microtubule‑associated proteins 1A/1B light chain 3B and Beclin‑1 expression. Additionally, western blot analysis identified that CTD inhibited the phosphatidylinositol 3‑kinase (PI3K)/RAC serine/threonine protein kinase (Akt)/mechanistic target of rapamycin (mTOR) signaling pathway in NSCLC, demonstrating that the levels of phosphorylated (p‑)Akt, p‑mTOR, phosphorylated ribosomal p70S6 protein kinase (p‑p70‑S6K) and cyclin D1 were significantly decreased following treatment with CTD. In conclusion, the results of the present study indicated that CTD impeded cell growth and migration by inhibiting PI3K/Akt/mTOR signaling in NSCLC, and promoted autophagy and apoptosis. CTD exhibited anticancer activity against NSCLC in vitro, revealing it as a potential candidate for the treatment of NSCLC.

View Figures

View References

1	Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al: Cancer treatment and survivorship statistics. CA Cancer J Clin. 64:220–241. 2012. View Article : Google Scholar
2	Blackhall F and Thatcher N: Chemotherapy for advanced lung cancer. Eur J Cancer. 40:2345–2348. 2004. View Article : Google Scholar : PubMed/NCBI
3	Grilli R, Oxman AD and Julian JA: Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol. 11:1866–1872. 1993. View Article : Google Scholar : PubMed/NCBI
4	Iwamoto T: Clinical application of drug delivery systems in cancer chemotherapy: Review of the efficacy and side effects of approved drugs. Biol Pharm Bull. 36:715–718. 2013. View Article : Google Scholar : PubMed/NCBI
5	Olaussen KA and Postel-Vinay S: Predictors of chemotherapy efficacy in non-small-cell lung cancer: A challenging landscape. Ann Oncol. 27:2004–2016. 2016. View Article : Google Scholar : PubMed/NCBI
6	Yamamoto Y and Iwase H: [Management for treatment-induced adverse reaction-chemotherapy]. Nihon Rinsho. 70 Suppl 7:S672–S676. 2012.
7	Rabinowitz JD and White E: Autophagy and metabolism. Science. 330:1344–1348. 2010. View Article : Google Scholar : PubMed/NCBI
8	Duffy A, Le J, Sausville E and Emadi A: Autophagy modulation: A target for cancer treatment development. Cancer Chemother Pharmacol. 75:439–447. 2015. View Article : Google Scholar : PubMed/NCBI
9	Li C, Wang Y, Wang C, Yi X, Li M and He X: Anticancer activities of harmine by inducing a pro-death autophagy and apoptosis in human gastric cancer cells. Phytomedicine. 28:10–18. 2017. View Article : Google Scholar : PubMed/NCBI
10	Wang B, Lu D, Xuan M and Hu W: Antitumor effect of sunitinib in human prostate cancer cells functions via autophagy. Exp Ther Med. 13:1285–1294. 2017. View Article : Google Scholar : PubMed/NCBI
11	White E: The role for autophagy in cancer. J Clin Invest. 125:42–46. 2015. View Article : Google Scholar : PubMed/NCBI
12	Parzych KR and Klionsky DJ: An overview of autophagy: Morphology, mechanism, and regulation. Antioxid Redox Signal. 20:460–473. 2014. View Article : Google Scholar : PubMed/NCBI
13	Xiong X, Wu M, Zhang H, Li J, Lu B, Guo Y, Zhou T, Guo H, Peng R, Li X, et al: Atg5 siRNA inhibits autophagy and enhances norcantharidin-induced apoptosis in hepatocellular carcinoma. Int J Oncol. 47:1321–1328. 2015. View Article : Google Scholar : PubMed/NCBI
14	Kim YM, Ku MJ, Son YJ, Yun JM, Kim SH and Lee SY: Anti-metastatic effect of cantharidin in A549 human lung cancer cells. Arch Pharm Res. 36:479–484. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zhang WD, Zhao HR, Yan Y, Wang XH, Zong ZH and Liu Y: Apoptosis induced by cantharidin in human pulmonary carcinoma cells A549 and its molecular mechanisms. Zhonghua Zhong Liu Za Zhi. 27:330–334. 2005.(In Chinese). PubMed/NCBI
16	Vanhaesebroeck B, Leevers SJ, Panayotou G and Waterfield MD: Phosphoinositide 3-kinases: A conserved family of signal transducers. Trends Biochem Sci. 22:267–272. 1997. View Article : Google Scholar : PubMed/NCBI
17	Pellegatta F, Chierchia SL and Zocchi MR: Functional association of platelet endothelial cell adhesion molecule-1 and phosphoinositide 3-kinase in human neutrophils. J Biol Chem. 273:27768–27771. 1998. View Article : Google Scholar : PubMed/NCBI
18	Ren Y, Zhang SW, Xie ZH, Xu XM, Chen LL, Lou ZG, Weng GB and Yao XP: Cantharidin induces G2/M arrest and triggers apoptosis in renal cell carcinoma. Mol Med Rep. 14:5614–5618. 2016. View Article : Google Scholar : PubMed/NCBI
19	Su CC, Lee KI, Chen MK, Kuo CY, Tang CH and Liu SH: Cantharidin induced oral squamous cell carcinoma cell apoptosis via the JNK-regulated mitochondria and endoplasmic reticulum stress-related signaling pathways. PLoS One. 11:e01680952016. View Article : Google Scholar : PubMed/NCBI
20	Zhang C, Chen Z, Zhou X, Xu W, Wang G, Tang X, Luo L, Tu J, Zhu Y, Hu W, et al: Cantharidin induces G2/M phase arrest and apoptosis in human gastric cancer SGC-7901 and BGC-823 cells. Oncol Lett. 8:2721–2726. 2014. View Article : Google Scholar : PubMed/NCBI
21	Liu B, Gao HC, Xu JW, Cao H, Fang XD, Gao HM and Qiao SX: Apoptosis of colorectal cancer UTC116 cells induced by Cantharidinate. Asian Pac J Cancer Prev. 13:3705–3708. 2012. View Article : Google Scholar : PubMed/NCBI
22	Li W, Xie L, Chen Z, Zhu Y, Sun Y, Miao Y, Xu Z and Han X: Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Sci. 101:1226–1233. 2010. View Article : Google Scholar : PubMed/NCBI
23	Anding AL and Baehrecke EH: Autophagy in cell life and cell death. Curr Top Dev Biol. 114:67–91. 2015. View Article : Google Scholar : PubMed/NCBI
24	Denton D, Xu T and Kumar S: Autophagy as a pro-death pathway. Immunol Cell Biol. 93:35–42. 2015. View Article : Google Scholar : PubMed/NCBI
25	Wang YX, Xu SQ, Chen XH, Liu RS and Liang ZQ: Autophagy involvement in olanzapine-mediated cytotoxic effects in human glioma cells. Asian Pac J Cancer Prev. 15:8107–8113. 2014. View Article : Google Scholar : PubMed/NCBI
26	Mihalache CC, Yousefi S, Conus S, Villiger PM, Schneider EM and Simon HU: Inflammation-associated autophagy-related programmed necrotic death of human neutrophils characterized by organelle fusion events. J Immunol. 186:6532–6542. 2011. View Article : Google Scholar : PubMed/NCBI
27	Hassan B, Akcakanat A, Holder AM and Meric-Bernstam F: Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am. 22:641–664. 2013. View Article : Google Scholar : PubMed/NCBI
28	Sheppard K, Kinross KM, Solomon B, Pearson RB and Phillips WA: Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog. 17:69–95. 2012. View Article : Google Scholar : PubMed/NCBI
29	Matsuoka T and Yashiro M: The role of PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers (Basel). 6:1441–1463. 2014. View Article : Google Scholar : PubMed/NCBI
30	Alao JP: The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Mol Cancer. 6:242007. View Article : Google Scholar : PubMed/NCBI